rly to
ea up
ok v e
Bo sa 500
d $
an
2nd
Stem Cells for
Drug Developers
Overcoming the Practical & Scientific
Challenges of iPSC & ESC Models
27th-29th March 2012, Boston
Benefits of attending
18 expert speakers including
• Understand the scientific mechanisms that control stem cell
differentiation to generate homogenous cell populations which
maintain the disease phenotype
Lee Rubin
Professor, Stem Cell & Regenerative
Biology
Harvard University
• Examine whether iPS cells can be a valid substitution for ESCs and
what their applications are for safety/toxicity testing
Sandra Engle
Senior Principal Scientist, Pluripotent
Stem Cell Biology
Pfizer
• Discuss strategies to promote full maturation of stem cell-derived
cell populations and advance your research efforts
• Overcome challenges in stem cell production to make sufficient
numbers for drug development
• Learn new approaches to achieve validation of your assay
• Harness the potential that iPS cells offer for individualized safety &
efficacy screening
Workshops: 27th March 2012
A)Developing Reproducible and Scalable Methods to Culture Stem
Cells: From the Microwell Plate to the Bioreactor
Jim Beltzer, Consultant, Beltzer Consulting Group
B)Integrating a Chemical Toolbox in Pluripotent Stem Cell Systems to
Advance Drug Development Programs: Emphasis on Small
Molecule-Mediated Modulation of Cell Fate
Dhruv Sareen, Director & Research Scientist I, iPSC Core Facility,
Cedars-Sinai Regenerative Medicine Institute
C)Understanding the Role of Stem Cell Factors and Functions to Aid
Drug Discovery Efforts
Ian Phillips, Norris Professor of Life Sciences & Director of the
Center for Rare Disease Therapies, Keck Graduate Institute
“Strong program,
great speakers and
a genuine focus on
identifying solutions”
“Outstanding…Excellent presentations,
variety, very good organization,
great networking sessions. Thanks for
preparing and please repeat next year!”
Novartis
GlaxoSmithKline
Tel: +44 (0) 203 141 8707 Email: [email protected]
Rudolf Jaenisch
Professor of Biology & Founding
Member
MIT & The Whitehead Institute
Joe Reynolds
Senior Scientist
Merrimack Pharmaceuticals
Mahendra Rao
Director, Center for Regenerative
Medicine
NIH
Christine Ivashchenko
Principal Scientist
GlaxoSmithKline
Hirdesh Uppal
Scientist
Genentech
Ole Isacson
Professor of Neurology, & Director,
Center for Neuroregeneration Research
Harvard Medical School & McLean Hospital
Jeff Dage
Senior Research Advisor
Eli Lilly
Karen Chandross
Director, Early to Candidate Unit
Sanofi
2nd Stem Cells for Drug Developers
Boston
Benefits of attending
Understanding complex disease mechanisms. Improving safety assessments.
Identifying new drug targets.
Drug developers universally indicate that stem cell-derived models will improve many
aspects of the drug development process and save valuable time and money. So the
rationale is simple, and the benefits are obvious. But it all comes back to HOW.
How can the scientific and practical challenges be overcome to harness the full
potential of stem cells?
The 2nd Stem Cells for Drug Developers meeting will bring together the leading
scientists from Pfizer, Harvard University, GlaxoSmithKline, McLean Hospital,
Novartis, Genentech, The Whitehead Institute and Merrimack Pharmaceuticals
to reveal how they are already using stem cells to add value to their discovery and
development programs. Learn, network and discuss how to revolutionize your drug
discovery and development efforts using stem cell-derived models.
1. Novartis, Merrimack Pharmaceuticals and Abbott will discuss how they are
building stem cell models for use in drug screening and safety/toxicology
assessments to understand the mechanisms of drug induced toxicity
2. Discover how iPSCs and ESCs can be used in disease research to increase your
understanding of molecular disease mechanisms with The Whitehead Institute,
McLean Hospital and The Medical College of Wisconsin
27th-29th March 2012
Hear what attendees said
about our Stem Cells for
Drug Developers meeting,
April 2011:
“Excellent overview of pharma’s
interests and opportunities”
Merck
“This was a great event to
gain insight into the broad
approaches of stem cells in
the drug discovery space”
Beckman Coulter
3. GSK will outline their strategies to ensure in vitro maturation of iPSC –
differentiated cardiomyocytes and Regeneron Pharmaceuticals will explore
the use of 3D models to enhance functionality and morphology of ESC derived
lineages
4. Find out how Eli Lilly, Pfizer, Sanofi and AVEO Pharmaceuticals are incorporating
stem cells into their drug discovery activities for toxicity evaluation and to develop
more predictive cellular assay systems
5. The NIH will discuss how to design a robust and scalable process to manufacture
iPSC-derived motor neurons and achieve sufficient numbers for drug development
purposes
“Nicely balanced cross
sections of the current state
of stem cell applications”
Pfizer
6. Learn how to differentiate stem cells more accurately by listening to how Harvard
University and Wellstat Therapeutics are controlling stem cell fate into desired
lineages
7. Cut through the hype and understand how Genentech, Pfizer, Novartis and GSK
are already benefitting from using iPSCs in the R&D process
8. Gain valuable insight into how Johnson & Johnson is overcoming challenges to
validate preclinical and clinical assays and avoid immunological pitfalls in assay
development
“Informative with fantastic
networking opportunities,
very well organized”
Harvard University
Who should attend?
This meeting has been designed to provide cutting edge insights for drug developers
to find the best way to incorporate stem cell-derived models into drug discovery &
development. It’s also a fantastic occasion for companies currently focused on stem
cell therapy to explore new opportunities and generate revenue in the near-term.
From using stem cells in disease research to safety/toxicology assessment and recent
breakthroughs in iPS cell technology, this meeting is for those involved in:
•
•
•
•
•
Stem cell biology & research
Drug discovery & development
Safety & toxicology assessment
Disease research
Target identification & validation
•
•
•
•
•
Genetic models
Regenerative medicine
Clinical strategy/development
R&D strategy
Commercial development
“Excellent depth of
information on the topic”
Aldagen
“Excellent content”
BD Technologies
Search groups for Stem Cells for Drug Discovery
Forum to join the online community.
Tel: +44 (0) 203 141 8707 Email: [email protected]
2nd Stem Cells for Drug Developers
Keynote Session
Panel Session
Boston
27th-29th March 2012
Networking Session
28th March 2012
Day 1
08.00Registration, Coffee and Networking
08.55Chair’s Opening Remarks
Ole Isacson, Professor of Neurology, & Director,
Center for Neuroregeneration Research,
Harvard Medical School & McLean Hospital
Using Stem Cells To Model Disease
09.00iPS Cell Technology and Disease Research: Issues to be
Resolved
• Key issues using iPS cells for disease research and
therapy including gene targeting
• Quality of iPS and ES cells and reprogramming
mechanisms
Rudolf Jaenisch, Professor of Biology & Founding Member,
MIT & The Whitehead Institute
09.30New Paradigms for Modeling Neurodegenerative Disease
and Treatments with iPS Cells from Parkinson’s Disease
Patients
• Genetic and hereditary modeling of neurodegenerative
diseases in human neurons in vitro
• Overlapping cellular pathway and organelle dysfunction,
with different genotypes causing the same disease
• Rescue of cellular dysfunction by targeted actions of tool
compounds
Ole Isacson, Professor of Neurology, & Director,
Center for Neuroregeneration Research,
Harvard Medical School & McLean Hospital
10.00Modeling Neurodegenerative Diseases in a Dish
• Data identifying molecular mechanisms of motor neuron
loss in spinal muscular atrophy (SMA) stem cells
• Data testing therapeutic compounds in SMA stem cells
• Possible complications to using stem cell based assays
for neurodegenerative diseases
Allison Ebert, Assistant Professor, Department of Cell
Biology, Medical College of Wisconsin
10.30Speed Networking Session and Morning Refreshments
Overcoming Challenges In Using Stem Cells
In Drug Discovery
12.00Novel Stem Cell Based Approaches to Modeling Cancer
• Preclinical models for oncology and other disease areas
• Discovery of predictive biomarkers in preclinical models
• Translating preclinical discovery into clinical research
Joerg Heyer, Director, Cancer Biology,
AVEO Pharmaceuticals
12.30Integration of Human ESC/iPSC Derived Cells into Drug
Discovery
• Imperative for incorporating pluripotent stem cell
derived cells into drug discovery and current
applications
• Gaps and future directions for use of pluripotent stem
cell derived cells in drug discovery
Sandra Engle, Senior Principal Scientist, Pluripotent Stem
Cell Biology, Pfizer
1.00 Small Molecules to Stimulate Endogenous Repair in the
Nervous System
• Overview of the remyelination strategy and challenges
• Data from an orally bioavailable, brain penetrable
compound
• Stimulation of human oligodendrocyte progenitor cell
differentiation in vitro, in a concentration dependent
manner
Karen Chandross, Director, Early to Candidate Unit, Sanofi
1.30 Lunch and Networking
Controlling Stem Cell Differentiation
Into Desired Lineages
2.30 Increasing our Understanding of Signaling Pathways
Involved in Stem Cell Differentiation to Advance
Research Efforts
• Differentiation protocols for ESCs and iPSCs
• Enhancing efficiency of reprogramming
Lee Rubin, Professor, Stem Cell & Regenerative Biology,
Harvard University
3.00 Directed Differentiation of Stem Cells Co-Cultured with
OP9-DL1 Cells into Engraftable T-Progenitors
• OP9-DL1 cells induce the stage-specific differentiation
of stem cells into T-lineage cells
• Two human T-progenitor cell populations have been
identified that exhibit rapid immune-engraftment within
immunodeficient mouse models
• Human T-progenitor cells differentiate into mature
functional T cells
Ross La Motte-Mohs, Senior Scientist,
Wellstat Therapeutics
3.30 Afternoon Refreshments and Networking
4.00 DNA Methylation Dynamics in Stem Cells and
Development
• Methylation dynamics in early development
• Epigenetic variation in stem cells
• Non-CG methylation in stem and differentiated cells
• Epigenetic reprogramming
Alexander Meissner, Assistant Professor,
Harvard Stem Cell Institute
4.30 Addressing the Gaps in Stem Cell Derived Models to
Promote Wider Adoption in this Field
• What are the limitations of current systems and how can
stem cells enhance the predictivity of in vitro models?
• Where do the knowledge gaps lie?
Sandra Engle, Senior Principal Scientist, Pluripotent Stem
Cell Biology, Pfizer, Gary Gintant, Senior Group Leader,
Abbott, & Christine Ivashchenko, Principal Scientist, GSK
5.00 Chair’s Closing Remarks
7.00 Networking Dinner
Share discussions with your peers and enjoy a relaxing and
informal dinner in comfortable surroundings. Good food,
good wine, good company!
Tel: +44 (0) 203 141 8707 Email: [email protected]
2nd Stem Cells for Drug Developers
Keynote Session
Boston
27th-29th March 2012
Networking Session
29th March 2012
Day 2
08.00Registration, Coffee and Networking
08.55Chair’s Opening Remarks
Gary Gintant, Senior Group Leader, Abbott
Generating Fully Matured Cell Populations
09.00Strategies to Promote In Vitro Maturation of Stem CellDerived Cardiomyocytes
• Functionality of in vitro hiPS-differentiated
cardiomyocytes (hiPS-CM)
• Equivalency of hiPS-CM to cells isolated from a mature
organ
• Strategies to promote hiPS-CM maturation
• Genetic models and high content screening in hiPS- CM
Christine Ivashchenko, Principal Scientist,
GlaxoSmithKline
09.303D Culture Models for Tissue-Specific Stem Cells and
Cancer Stem Cells, In Vivo and In Vitro
• VelociGene platform allows for rapidly generating
desired genetic modifications in mouse embryonic
stem cells
• Genetically modified mouse ES cells can be
differentiated into desired lineages using in vitro and
in vivo protocols
• 3D culture models act as readouts for modulation of
stemness and/or lineage specification
Courtney M Williams, Scientist,
Regeneron Pharmaceuticals
Advances In Stem Cell Manufacturing
10.00Manufacturing Functional Motor Neurons from Human
Pluripotent Stem Cells
• Expansion and differentiation of neural cells
• Designing a robust and scalable manufacturing process
Mahendra Rao, Director, Center for Regenerative Medicine,
NIH
10.30Morning Refreshments and Networking
Stem Cells For Drug Screening
& Safety/Toxicity Assessment
11.00Assessing Surrogates of Clinical Cardiotoxicity Using Stem
Cell-Derived Cardiomyocytes
• Demonstrate approach to preclinically assess drug safety
using stem cell derived models
• Understanding the mechanism of action of drug-induced
cardiotoxicity
• Translating preclinical toxicity results to the clinic
Joe Reynolds, Senior Scientist, Merrimack Pharmaceuticals
11.30High-Throughput Screening Using Stem Cell-Based
Models: Turning an Innovative Technology into a
Transformative Approach to Drug Design
• Stem cell-based approaches have the potential to
revolutionize the practice of medicine
• Many stem cell-related concepts are radically different
from those of traditional R&D; therefore integrating them
into today’s pharma culture raises a number of
challenges
• Developing stem cell-based projects inside a
pharmaceutical company from disease modeling to
high-throughput screening
Arnaud Lacoste, Project Team Leader - Stem Cells &
Regenerative Medicine, Novartis
12.00Lunch and Networking
1.15 Preclinical Assessment of Cardiac Safety/Toxicity Using
Stem Cells: Strengths, Limitations & Future Possibilities
• Advantages of cardiac stem cells in safety/toxicity
screening
• Assays and models presently used in pharma
• Integration of stem cells in safety assessments and
evolving strategies
• What can we do better?
Gary Gintant, Senior Group Leader, Abbott
Comparing The Utility of ESCs & iPSCs
1.45 What are the Pros and Cons of Using ESCs and iPSCs
and What are their Applications for Safety and Toxicity
Assessment?
• Advantages and disadvantages of ESCs and iPSCs
• Comparing preclinical predictivity of stem cell-derived
models with primary cell models
• Stem cell technology application strategy in drug
development: Cardiotoxicity, hematopoietic
toxicity and hepatotoxicity
Hirdesh Uppal, Scientist, Genentech
2.15 Afternoon Refreshments and Networking
Ensuring Proper Assay Development
2.45 iPSC-Derived Neurons as a Physiologically Relevant
Model for Drug Discovery
• Role of cell models in drug discovery • Development and validation of an iPS derived neuronal
cell model
• Application of iPS derived neuronal models to drug
discovery
Jeff Dage, Senior Research Advisor, Eli Lilly
3.15 Developing and Validating Preclinical and Clinical Assays
to Measure Immunological Response
• Allogeneic versus xenogeneic modeling
• Preclinical assay development: Learning the
immunological pitfalls
• Clinical immunogenicity monitoring
• Considerations for clinical trials
Sicco Popma, Principal Research Scientist, Stem Cell
Organization, Johnson & Johnson
3.45 Chair’s Closing Remarks
Tel: +44 (0) 203 141 8707 Email: [email protected]
2nd Stem Cells for Drug Developers
Boston
27th-29th March 2012
Workshop A: Developing Reproducible and Scalable Methods to
Culture Stem Cells: From the Microwell Plate to the Bioreactor
Date: 27th March 2012
Time: 8.30am – 11.30am
The culture of human embryonic stem cells (hESC) has begun to move from
the research laboratory toward various clinical applications. These applications
include: cell therapies, disease modeling and drug screening. Inherent to all of these
applications is the need for reproducible and scalable culture methods that preserve
the desirable traits of hESCs such as pluripotency, genetic stability, and growth rates.
Attendees will explore and discuss:
• Approaches to finding the right culture conditions to meet your needs
• Matrix, media and cell line considerations for optimal growth and performance
• Drivers for scale up, manufacturing concerns and potential bottlenecks
• Bags, bioreactors, micro-carriers, hollow fiber and fixed bed bioreactors
This course will describe the methods and the metrics that you will need to
successfully scale your hESC cultures from microwell plates to multi-liter bioreactors.
Workshop leader
Jim Beltzer
Consultant
Beltzer Consulting Group
Dr. Beltzer was the lead scientist for the research
and development of Synthemax™ a synthetic
growth surface for the culture of human
embryonic stem cells at Corning Life Sciences.
He was a co-founder of RETT Corporation and
was a key player in the industrialization of several
technology platforms including phage display
and yeast two-hybrid. He has more than twenty
years of industrial research and development
experience in a broad range of disciplines.
Workshop B: Integrating a Chemical Toolbox in Pluripotent Stem Cell
Systems to Advance Drug Development Programs: Emphasis on Small
Molecule-Mediated Modulation of Cell Fate
As induced pluripotent stem cells can be differentiated to virtually any tissue in the
body, they represent a new source of tissue for recreating human “disease-in-a-dish”
models. These cells can address a significant bottleneck in drug development by
providing physiologically-relevant functional human cell types in more predictive
cellular assay systems. This has resulted in the identification of a multitude of
functional small molecules involved in somatic/stem cell fate specification. Attendees
will discuss and debate:
• Current utilization of pluripotent stem cells (PSCs) in drug discovery
• Challenges associated with current iPSC technology
• Compounds currently involved in modulating PSC fate
• Specification of various cell populations from PSCs
• Characterizing small molecules using various approaches
Attendees will leave this workshop with the tools they need to incorporate small
molecules into their pluripotent stem cell research to advance their drug development
programs.
Workshop C: Understanding the Role of Stem Cell Factors and
Functions to Aid Drug Discovery Efforts
Stem cells not only have the potential to become therapies for disease, but
they can also be used in vitro to aid in drug discovery and drug testing, saving
companies time and money. Stem cells secrete growth factors that may be the
source of their therapeutic effect and studying these factors could lead to new
drugs. In addition microRNA regulates stem cells and specific inhibitors of stem
cell microRNAs could become new drugs for regulating stem cell genes. This
workshop will discuss:
• In vitro use of human stem cells for drug toxicity studies
• Paracrine hormones secreted by stem cells that may become drugs
• Antisense (antagomirs) for specific microRNA that regulate stem cells
Participants will leave this workshop with the knowledge they need to use stem
cells to aid their drug discovery efforts.
Tel: +44 (0) 203 141 8707 Email: [email protected]
Date: 27th March 2012
Time: 12pm – 3pm
Workshop leader
Dhruv Sareen
Director & Research Scientist I,
Stem Cell Core
Cedars-Sinai Medical Center
Dhruv Sareen, Ph.D. is currently the Director of
the Induced Pluripotent Stem Cell (iPSC) Core
Facility and a Research Scientist at Cedars-Sinai
Regenerative Medicine Institute.
Dr. Sareen received his Ph.D. from the University
of Wisconsin where he characterized novel
pharmacological pathways of resveratrol-induced
human tumor cell death and participated in its
preclinical drug-development program. Now he
is developing high-content screening tools using
SMA patient iPSCs to discover novel therapeutic
compounds.
Date: 27th March 2012
Time: 3.30pm – 6.30pm
Workshop leader
Ian Phillips
Norris Professor of Life Sciences
& Director of the Center for Rare
Disease Therapies
Keck Graduate Institute
Ian Phillips is the Norris Professor of Life Sciences
and Director of the Center for Rare Disease
Therapies at the Keck Graduate Institute in
Claremont, California. He received his PhD and
DSc in Pharmacology from the University of
Birmingham. He was Chairman of Physiology at
the University of Florida and Vice President of
Research at the University of South Florida before
he moved to KGI.
2nd Stem Cells for Drug Developers
Boston
27th-29th March 2012
Speakers
Karen Chandross
Director, Early to
Candidate Unit
Sanofi
Dr. Chandross supports the Early to
Candidate Unit’s efforts to develop
stimulators of endogenous tissue
repair and global R&D regenerative
medicine initiatives. She received
her PhD at the Albert Einstein
College of Medicine.
Gary Gintant
Senior Group Leader
Abbott
Gary Gintant is a Research
Fellow in the Dept. of Integrative
Pharmacology, Abbott Laboratories.
He is involved in multiple internal
and external drug discovery and
safety initiatives, and serves on
multiple journal editorial boards.
Rudolf Jaenisch
Professor of Biology &
Founding Member
MIT & The Whitehead
Institute
Rudolf Jaenisch is a Founding
Member of the Whitehead Institute
and a Professor of Biology at MIT.
His laboratory is exploring the role
of DNA modification, genomic
imprinting and the nature of stem
cells.
Sicco Popma
Principal Research
Scientist, Stem Cell
Organization
Johnson & Johnson
Sicco Popma is a Principal
Research Scientist at the
Stem Cell Organization of
Johnson & Johnson. He directs
preclinical and clinical stem cell
immunology, bio-distribution,
biomarker and drug delivery
research.
Hirdesh Uppal
Scientist
Genentech
Hirdesh Uppal is a Scientist in
Safety Assessment & Development
Sciences at Genentech. He’s
developing cutting edge stem
cell technologies to harness the
power of iPSCs to transform drug
discovery and enable the promise
of regenerative medicine.
Jeff Dage
Senior Research Advisor
Eli Lilly
Dr. Dage is a Senior Research
Advisor at Eli Lily and Company.
Through his leadership of the stem
cell platform team, Dr. Dage is
responsible for the evaluation and
implementation of stem cell based
research across drug discovery.
Allison Ebert
Assistant Professor,
Department of Cell
Biology
Medical College of
Wisconsin
Dr. Ebert is an assistant professor
in the Department of Cell Biology,
Neurobiology and Anatomy at
the Medical College of Wisconsin
where she uses stem cells to
model and potentially treat
neurodegenerative diseases.
Joerg Heyer
Director, Cancer
Biology
AVEO Pharmaceuticals
Dr. Heyer is heading AVEO
Pharmaceuticals Genetic Models
efforts supporting translational
research and biomarker discovery
for AVEO Pharmaceuticals drug
discovery programs. Dr. Heyer
received his Ph.D. at the Julius
Maximilians University Wuerzburg.
Ole Isacson
Professor of Neurology,
& Director, Center for
Neuroregeneration Research
Harvard Medical School &
McLean Hospital
Important recent scientific discoveries for neurological and psychiatric
diseases made in Dr. Isacson’s lab
through the use of ES and iPS cells
show how to model disease, provide
neuroprotection and how degenerated brain cell circuitry and synapses
can be restored or replaced.
Ross La Motte-Mohs
Senior Scientist
Wellstat Therapeutics
Arnaud Lacoste
Project Team Leader
- Stem Cells &
Regenerative Medicine
Novartis
Arnaud Lacoste is a Project
Team Leader at Novartis
where he pioneered the use of
reprogramming technologies
and patient-derived pluripotent
stem cells for drug discovery and
development.
Dr. La Motte-Mohs is a Senior
Scientist at Wellstat Therapeutics
and his laboratory focuses on
treating human T-immunodeficiency.
He received his doctorate from the
University of Illinois and completed
postdoctoral studies at the University
of Toronto.
Joe Reynolds
Senior Scientist
Merrimack
Pharmaceuticals
Mahendra Rao
Director, Center for
Regenerative Medicine
NIH
Dr. Rao is internationally renowned
for his research involving
human embryonic stem cells
(hESCs) and other somatic stem
cells. He received his Ph.D. in
developmental neurobiology
from the California Institute of
Technology.
Courtney M Williams
Scientist
Regeneron
Pharmaceuticals
Courtney M. Williams is currently
a Scientist in the Oncology and
Angiogenesis group at Regeneron.
Her work focuses on designing/
implementing in vitro cell culture
systems for cancer stem cell target
validation
Joe is a Senior Scientist at
Merrimack Pharmaceuticals in
their Research and Development
group working on the clinical
candidate MM-302. He received
his PhD from Boston University in
Molecular, Cellular Biology and
Biochemistry.
Sandra Engle
Senior Principal
Scientist, Pluripotent
Stem Cell Biology
Pfizer
Sandra Engle is a Senior Principal
Scientist in the Pluripotent
Stem Cell Biology Laboratory
within Pfizer. Her lab focuses on
generating iPSCs, differentiation
of stem cells and the genetic
modification of human stem cells.
Christine Ivashchenko
Principal Scientist
GlaxoSmithKline
Christine Ivashchenko is a principal
scientist at GlaxoSmithKline
pharmaceuticals. Her current
research focus is on the use of
stem-cell derived cardiomyocytes
in the discovery of novel heart
failure therapeutics.
Alexander Meissner
Assistant Professor
Harvard Stem Cell
Institute
Alex Meissner joined Harvard
University as assistant professor in
the department of stem cell and
regenerative biology. He is also
a senior associate member of the
Broad Institute.
Lee Rubin
Professor, Stem Cell &
Regenerative Biology
Harvard University
Dr. Rubin is Professor of Stem
Cell and Regenerative Biology at
Harvard University. His lab uses
stem cell-based screens to identify
therapeutics for orphan neural
disorders and explores different
chemical biology approaches for
manipulating cell fate.
“The speaker array
and order was perfect
and allowed me to
take the maximal
amount of knowledge
back to the lab”
“Excellent state-of-the-art
for in vitro technology
and practical pharma
examples. An extremely
good snapshot of where
the field is”
Novartis
Katya Tsaioun
CSO
Cyprotex
Tel: +44 (0) 203 141 8707 Email: [email protected]
2nd Stem Cells for Drug Developers
Sponsorship opportunities
27th-29th March 2012
Working with Hanson Wade
If your organization needs
to raise profile, promote
products and services or
develop new partnership
opportunities in the stem
cell sector, contact:
Miles Harley
Boston
tel: +44 (0)20 3141 8700
email: [email protected]
When you work with Hanson Wade you work with a partner
focussed on your success. Your investment in both time and
money needs to generate a return.
Our clients want that too and that’s why they work with us. They
want to reach a targeted audience and eliminate wastage from
their marketing activities. They work with us because we deliver
results. We’re proud of this fact.
Our research identifies ground breaking issues and allows you
to influence industry thinking at an early stage. Our expertise
is recognised and respected by the industry. And our events
are focussed, leading edge and attended by people looking for
knowledge before making decisions.
Attendee breakdown
Attendee breakdown at the last meeting
Seniority breakdown at the last meeting
14%
17%
Scientist/Group
Leader/Manager
Large Pharma/Biotech
48%
Academia
35%
51%
Service Provider
35%
Speaker Organizations
Media Partners
SCR
StemCellResources.org
the science of education
Tel: +44 (0) 203 141 8707 Email: [email protected]
Director
Vice President
2nd Stem Cells for Drug Developers
Boston
27th-29th March 2012
DSN
Priority Code:
Event prices
Register
Mail:
Hanson Wade
Charter House
13-15 Carteret St
London, SW1H 9DJ
Tel: +44 (0)20 3141 8707
Email: [email protected]
Package
Register and pay
before Friday 20th
January*
Register and pay
before Friday 10th
February*
Standard
Price
Conference +
3 workshops +
Networking Dinner**
$3596
(SAVE $500)
$3696
(SAVE $400)
$3796
(SAVE $300)
Conference +
2 workshops +
Networking Dinner**
$3097
(SAVE $400)
$3197
(SAVE $300)
$3497
Please note that discounts are only valid when three or more
delegates from one company book and pay at the same time.
Conference +
1 workshop +
Networking Dinner**
$2598
(SAVE $300)
$2698
(SAVE $200)
$2898
Venue and accommodation
Conference +
Networking Dinner**
$2099
(SAVE $200)
$2199
(SAVE $100)
$2299
Half day workshop
$599
$599
$599
Team discounts
• 10% discount – 3 delegates
• 15% discount – 4 delegates
• 20% discount – 5 or more delegates
Venue
DoubleTree Suites by Hilton Hotel Boston
400 Soldiers Field Road, Boston, Massachusetts, United States
02134-1893, Tel: 1-617-783-0090.
Accommodation
Accommodation is not included in your fee. You will be sent
accommodation options upon registration.
Purchase audio presentations
If you are unable to attend the meeting in person or would like
documentation in addition to your attendance you may purchase
the audio recordings of the speaker presentations for $799.
These will be sent to you on CD rom with all available presentation
slides within 10 days of the meeting. Audio orders can only be
processed on receipt of credit card details.
Please select your choice of workshop:
A
B
**To opt out of the networking dinner please tick here
from your package price.
C
$100 will be discounted
A 40% discount is available for academics and not for profit organizations, please email
[email protected] for more information or to register.
*All discount offers (including team discounts) require payment at the time of registration
to receive any discount. ‘Early Bird’ discounts require payment at time of registration
and on or before the cut-off date to receive any discount. All discount offers cannot be
combined with any other offer. The conference fee includes lunch, refreshments and
course documentation. The fee does not include travel or hotel accommodation.
Delegate details
Title:
Forename:
Surname:
Job Title:
Company/Organization:
Email:
Direct Manager:
Country:
Direct Telephone:
Direct Fax:
Mobile:
Switchboard:
Signature:
Address:
Postcode:
Date:
Payment details
Number of delegates
Amount: $
Conference Documentation
Credit Card:
Visa
Card No:
Valid from: /
Mastercard
Amex
Expiry Date: /
Cardholders name:
Signature:
Date:
Card billing address:
TERMS & CONDITIONS
Changes to Conference & Agenda: Hanson Wade reserves the right to
postpone or cancel an event, to change the location or alter the advertised
speakers. Hanson Wade is not responsible for any loss or damage or costs
incurred as a result of substitution, alteration, postponement or cancellation
of an event for any reason and including causes beyond its control
including without limitation, acts of God, natural disasters, sabotage,
accident, trade or industrial disputes, terrorism or hostilities
Data Protection The personal information shown and/or provided by you
will be held in a database. It may be used to keep you up to date with
developments in your industry. Sometimes your details may be obtained or
made available to third parties for marketing purposes. If you do not wish
your details to be used for this purpose, please write to: Database Manager,
Hanson Wade, Charter House, 13-15 Carteret Street, London SW1H 9DJ
Hanson Wade Limited. Registered in England & Wales. Company No: 6752216
Tel: +44 (0) 203 141 8707 Email: [email protected]
Code: 2050
Full payment is due on registration.Cancellation and Substitution Policy:
Cancellations must be received in writing. If the cancellation is received
more than 14 days before the conference attendees will receive a full credit
to a future conference. Cancellations received 14 days or less (including the
fourteenth day) prior to the conference will be liable for the full fee.
A substitution from the same organisation can be made at any time.